Drug Database
Back to search

Poland· PL-100433440

Xonvea

A gestodene and ethinylestradiol product containing doxylamini hydrogenosuccinas + pyridoxini hydrochloridum, registered in Poland by Exeltis Poland Sp. z o.o.. The same ATC class is registered in 9 of our 19 countries.

ATC G03AA10

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedXonveaATCG03AA10REGISTER NO.PL-100433440PACKS LISTED6CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about doxylamini hydrogenosuccinas + pyridoxini hydrochloridumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Gestodene and ethinylestradiol is registered in 9 of 19 countries.

Countries holding a registration under ATC G03AA10 (gestodene and ethinylestradiol), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 6 of them publish a price we can compare per daily dose
Search gestodene and ethinylestradiol products by name

Gestodene and ethinylestradiol · ATC G03AA10

9 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Doxylamini hydrogenosuccinas + Pyridoxini hydrochloridum
Manufacturer
Exeltis Poland Sp. z o.o.
Country
Poland (PL)
ATC code
G03AA10
ATC class
Gestodene and ethinylestradiol
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 6

  • gtin
    05909991472726
  • gtin
    05909991472733
  • gtin
    05909991472740
  • gtin
    05909991472757
  • gtin
    05909991472764
  • gtin
    05909991472719

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

31 interactions on record for gestodene and ethinylestradiol.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check gestodene and ethinylestradiol against other medicinesHow interaction checks work

Gestodene and ethinylestradiol · interactions on record

31 records

31 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Gestodene and ethinylestradiol in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All gestodene and ethinylestradiol products

Authorised across Europe · EMA

The same active substance is authorised in 26 EEA countries. Names it is sold under:

  • Austria · Nuperal, Xonvea
  • Belgium · Bonjesta, Navalit
  • Bulgaria · Нюперал
  • Cyprus · Nuperal
  • Czechia · Nuperal, Xonvea
  • Germany · Cariban, Cariban 10 Mg/10 Mg
  • Denmark · Bonjesta, Xonvea
  • Estonia · Xonvea
  • Spain · Bonjesta, Cariban
  • Finland · Bonjesta, Xonvea
  • France · Cariban, Xonvea
  • United Kingdom (Northern Ireland) · Xonvea
  • Greece · Nuperal
  • Hungary · Nuperal, Vombee
  • Ireland · Cariban, Doxpirexel
  • Iceland · Xonvea
  • Italy · Bonjesta, Embagyn
  • Lithuania · Xonvea
  • Luxembourg · Bonjesta, Bonjesta 20/20
  • Latvia · Xonvea
  • Netherlands · Embagyn, Navalit
  • Norway · Embagyn, Xonvea
  • Portugal · Bonjesta, Cariban
  • Romania · Nuperal
  • Sweden · Bonjesta, Xonvea
  • Slovakia · Nuperal, Xonvea

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c65f0af2-d286-400b-a1ff-042456183ed6
GET /v1/drugs/c65f0af2-d286-400b-a1ff-042456183ed6?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki dojelitowe",
  "source": "urpl",
  "strength": "10 mg + 10 mg",
  "packaging": "05909991472719 ¦ Rp ¦ 142987\n10 tabl.\n05909991472726 ¦ Rp ¦ 142988\n40 tabl.\n05909991472733 ¦ Rp ¦ 142989\n50 tabl.\n05909991472740 ¦ Rp ¦ 142990\n30 tabl.\n05909991472757 ¦ Rp ¦ 142991\n60 tabl.\n05909991472764 ¦ Rp ¦ 142992\n20 tabl.",
  "substance": "Doxylamini hydrogenosuccinas 10 mg + Pyridoxini hydrochloridum 10 mg",
  "common_name": "Doxylamini hydrogenosuccinas + Pyridoxini hydrochloridum",
  "pl_product_id": "100433440",
  "pozwolenie_nr": "26827",
  "auth_procedure": "DCP",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about gestodene and ethinylestradiol.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console